DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Obatoclax is an investigational drug.
There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, and Lung Neoplasms. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.
There are four hundred and seventy-eight US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Obatoclax
|Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer||Cephalon||Phase 3|
|Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|Obatoclax for Systemic Mastocytosis||Gemin X||Phase 2|
Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Obatoclax||Try Before You Buy||Pyrazol-3-ones that activate pro-apoptotic BAX||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Try Before You Buy|
|Obatoclax||Try Before You Buy||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Try Before You Buy|
|Obatoclax||Try Before You Buy||Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor||The Regents of the University of California (Oakland, CA)||Try Before You Buy|
|Obatoclax||Try Before You Buy||Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy||University of Georgia Research Foundation Inc. (Athens, GA)||Try Before You Buy|
|Obatoclax||Try Before You Buy||Formulations for tailored drug release||South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD)||Try Before You Buy|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Obatoclax||Australia||AU2012322660||2031-10-11||Try Before You Buy|
|Obatoclax||Australia||AU2017228527||2031-10-11||Try Before You Buy|
|Obatoclax||Canada||CA2851788||2031-10-11||Try Before You Buy|
|Obatoclax||European Patent Office||EP2766355||2031-10-11||Try Before You Buy|
|Obatoclax||World Intellectual Property Organization (WIPO)||WO2013055949||2031-10-11||Try Before You Buy|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|